33,230 Shares in Inogen, Inc (NASDAQ:INGN) Purchased by XTX Topco Ltd

XTX Topco Ltd bought a new stake in Inogen, Inc (NASDAQ:INGN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 33,230 shares of the medical technology company's stock, valued at approximately $237,000. XTX Topco Ltd owned about 0.12% of Inogen as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in INGN. Wealth Enhancement Advisory Services LLC bought a new stake in Inogen in the first quarter valued at $99,000. CWM LLC lifted its stake in Inogen by 71.7% in the first quarter. CWM LLC now owns 14,647 shares of the medical technology company's stock valued at $104,000 after buying an additional 6,118 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Inogen by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock valued at $128,000 after buying an additional 3,031 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Inogen in the fourth quarter valued at $135,000. Finally, Graham Capital Management L.P. bought a new stake in Inogen in the fourth quarter valued at $138,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Price Performance

Shares of NASDAQ INGN traded down $0.21 during midday trading on Friday, reaching $7.46. 182,241 shares of the company traded hands, compared to its average volume of 284,956. Inogen, Inc has a 52 week low of $5.70 and a 52 week high of $13.33. The stock has a 50-day moving average price of $6.80 and a 200 day moving average price of $7.46. The company has a market cap of $201.72 million, a price-to-earnings ratio of -7.04 and a beta of 1.72.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. The business had revenue of $92.28 million for the quarter, compared to analysts' expectations of $90.40 million. As a group, analysts expect that Inogen, Inc will post -1.73 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. B. Riley assumed coverage on Inogen in a research note on Monday, June 16th. They issued a "buy" rating and a $14.00 target price on the stock. Needham & Company LLC upgraded Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price on the stock in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus cut their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.